AVANOS MEDICAL, INC. (NYSE:AVNS) Sees Large Increase in Short Interest

Key Points

• Short interest in AVANOS MEDICAL increased by 25.8% in July, now totaling 1,900,000 shares, indicating a growing bearish sentiment among investors.
• Director Gary Blackford purchased 40,000 shares of AVANOS MEDICAL stock at an average price of $10.99, representing a significant personal investment in the company.
• AVANOS MEDICAL reported earnings per share (EPS) of $0.17 for the last quarter, missing analysts’ expectations, while setting a FY 2025 guidance of 0.750-0.950 EPS.

AVANOS MEDICAL, INC. (NYSE:AVNS - Get Free Report) was the target of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 1,900,000 shares, agrowthof25.8% from the July 15th total of 1,510,000 shares. Based on an average daily volume of 491,900 shares, the short-interest ratio is presently 3.9 days. Approximately4.2% of the shares of the company are short sold. Approximately4.2% of the shares of the company are short sold. Based on an average daily volume of 491,900 shares, the short-interest ratio is presently 3.9 days.

Insider Buying and Selling at AVANOS MEDICAL

In other AVANOS MEDICAL news, Director Gary Blackford acquired 40,000 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The stock was acquired at an average price of $10.99 per share, with a total value of $439,600.00. Following the transaction, the director owned 40,000 shares of the company's stock, valued at approximately $439,600. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.64% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AVNS. Armistice Capital LLC acquired a new stake in AVANOS MEDICAL during the 1st quarter worth $28,660,000. T. Rowe Price Investment Management Inc. raised its stake in AVANOS MEDICAL by 24.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,757,576 shares of the company's stock worth $53,847,000 after buying an additional 746,264 shares during the period. Clark Estates Inc. NY acquired a new stake in AVANOS MEDICAL during the 1st quarter worth $7,077,000. Millennium Management LLC raised its stake in AVANOS MEDICAL by 508.3% during the 1st quarter. Millennium Management LLC now owns 547,740 shares of the company's stock worth $7,849,000 after buying an additional 457,703 shares during the period. Finally, Pacer Advisors Inc. acquired a new stake in AVANOS MEDICAL during the 1st quarter worth $6,056,000. Institutional investors and hedge funds own 95.17% of the company's stock.

Analyst Ratings Changes

AVNS has been the topic of several analyst reports. Wall Street Zen lowered AVANOS MEDICAL from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Zacks Research upgraded AVANOS MEDICAL to a "hold" rating in a research note on Tuesday, August 12th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of "Hold".

AVANOS MEDICAL Price Performance

NYSE AVNS traded up $0.31 during trading hours on Wednesday, reaching $11.89. 515,247 shares of the company's stock were exchanged, compared to its average volume of 825,548. The stock has a market cap of $551.79 million, a PE ratio of -1.18 and a beta of 1.12. AVANOS MEDICAL has a one year low of $9.30 and a one year high of $25.36. The firm has a fifty day moving average of $11.63 and a 200-day moving average of $12.92. The company has a current ratio of 2.64, a quick ratio of 1.58 and a debt-to-equity ratio of 0.12.

AVANOS MEDICAL (NYSE:AVNS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $175.00 million during the quarter, compared to the consensus estimate of $165.50 million. AVANOS MEDICAL had a negative net margin of 66.89% and a positive return on equity of 6.16%. During the same quarter in the previous year, the business posted $0.34 earnings per share. AVANOS MEDICAL has set its FY 2025 guidance at 0.750-0.950 EPS. On average, equities research analysts predict that AVANOS MEDICAL will post 1.32 earnings per share for the current fiscal year.

AVANOS MEDICAL Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.